ReviewJournal of thoracic disease2021
Bacterial infections in lung transplantation.
Review in Journal of thoracic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Risk of Donor-Derived Infections From Organ Donors Colonized or Infected With Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review and Meta-Analysis.Clinical transplantation · 2026Pooled it
- Global challenges of bacterial infections in organ transplantation: assessment of risk factors and predominant bacterial pathogen profiles threatening liver, kidney, heart, and lung transplant recipients.BMC infectious diseases · 2025Pooled it
- Inhaled sphingosine reduces bronchial Pseudomonas aeruginosa burden during porcine ex vivo lung perfusion and shows tissue delivery in explanted human lungs.Scientific reports · 2026Article
- Treatment of post-lung transplantation pneumonia with cefiderocol: a case series and insights from the literature.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Review
- Anomalous Lobar Variations in Donor Lung: Challenges and Considerations in Lung Transplantation.Cureus · 2026Article
- The Myeloid-T Lymphocyte Axis in Chronic Lung Allograft Rejection: Emerging Insights into the Immune Circuitry Driving Fibrosis.Results and problems in cell differentiation · 2026Review
- Enrichment of the commensal microbiome in the lower respiratory tract is associated with improved outcomes following lung transplantation.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Impact of Mild-to-Moderate Donor Lung Infiltration on Post-lung Transplant Survival Outcomes and Risk Factors: A National Cohort Study.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025Article
- Management of microaspiration and gastrointestinal dysfunction after lung transplantation: A narrative review.JHLT open · 2025Review
- Clinical Characteristics, Outcomes, and Distribution Patterns of Pathogens Causing Respiratory Infections in Lung Retransplant Recipients.Antibiotics (Basel, Switzerland) · 2025Article
- Increasing risk of postlung transplant hospitalizations for infection: An analysis of recent trends.JHLT open · 2025Article
- Lung transplant: A clinical overview.Clinical medicine (London, England) · 2025Review
- Exploring the Association BetweenBiomolecules · 2025Article
- Multidrug-resistant Gram-negative bacteria in lung transplantation: a narrative review of infectious complications and current management.Frontiers in microbiology · 2025Review
- The application of ERAS in the perioperative period management of patients for lung transplantation.Surgery open science · 2024Article
- Article
- Unique Changes in the Lung Microbiome following the Development of Chronic Lung Allograft Dysfunction.Microorganisms · 2024Article
- Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Analysis of high-risk factors for early pulmonary bacterial infection after lung transplantation and their correlation with long-term mortality.American journal of translational research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation has lower survival rates compared to other than other solid organ transplants (SOT) due to higher rates of infection and rejection-related complications, and bacterial infections (BI) are the most frequent infectious complications. Excess morbidity and mortality are not only a direct consequence of these BI, but so are subsequent loss of allograft tolerance, rejection, and chronic lung allograft dysfunction due to bronchiolitis obliterans syndrome (BOS). A wide variety of pathogens can cause infections in lung transplant recipients (LTRs), including a number of nosocomial pathogens and other multidrug-resistant (MDR) pathogens. Although pneumonia and intrathoracic infections predominate, LTRs are at risk of a number of types of infections. Risk factors include altered anatomy and function of airways, impaired immunity, the microbial flora of the donor and recipient, underlying medical conditions, and genetic factors. Further work on immune monitoring has the potential to improve outcomes. The infecting agents can be derived from the donor lung, pre-existing recipient flora, or acquired from the environment over time. Certain infections may preclude lung transplantation, but this varies from center to center, and more recent studies suggest fewer patients should be disqualified. New molecular methods allow microbiome studies of the lung, gut, and other sites that may further our knowledge of how airway colonization can result in infection and allograft loss. Surveillance, early diagnosis, and aggressive antimicrobial therapy of BI is critical in LTRs. Antibiotic resistance is a major barrier to successful management of these infections. The availability of new agents for MDR Gram-negatives may improve outcomes. Other new therapies, such as bacteriophage therapy, show promise for the future. Finally, it is important to prevent infections through peri-transplant prophylaxis, vaccination, and infection control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.